Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07777315

Group DBT Skills Training for First Episode Psychosis

Psychosis is a serious mental health condition that can affect how a person thinks, feels, and functions in daily life, often making it harder to maintain relationships, continue education, or work. Even with standard treatment, many people continue to experience emotional distress, depression, anxiety, and difficulty coping with strong emotions. These challenges can worsen recovery, increase the risk of substance use and suicidal behaviour, and place a significant burden on individuals, families, and the healthcare system.

Dialectical Behaviour Therapy (DBT) is a skills-based psychological treatment that helps people manage emotions, tolerate distress, and improve relationships. Although DBT has been effective in other mental health conditions, it has not been well studied in people with first-episode psychosis.

This study will evaluate an 8-week group DBT skills training adapted for individuals with first-episode psychosis. The study aims to assess whether the program is acceptable and feasible to deliver, and whether it may improve emotion regulation, mood, resilience, and functioning. Findings will inform whether a larger clinical trial of this intervention should be conducted.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

14 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Despite evidence that individuals with psychotic disorders experience marked emotion dysregulation, impulsivity and elevated suicide risk, they have largely been excluded from clinical trials evaluating DBT. Nevertheless, emerging pilot studies support the feasibility and potential efficacy of brief DBT-informed skills group in individuals with psychosis, with participants reporting high satisfaction and improvements in understanding and managing emotions, suicidality, and interpersonal functioning. However, this literature remains preliminary and underdeveloped, and no studies have evaluated group DBT skills intervention specifically for individuals with first-episode psychosis.

Aim 1: To evaluate the acceptability of the group DBT skills training invention and the feasibility of conducting a fully powered randomized controlled trial (RCT) of in young men with psychosis.

Aim 2: To assess the preliminary efficacy of group DBT skills training in improving emotion regulation, resilience, and functioning and reducing, mood and anxiety and substance use, in a single-arm exploratory clinical trial.

This study will provide evidence of the feasibility, acceptability, and preliminary efficacy of a group DBT skills training for young men with first-episode psychosis. Findings will advance understanding of emotion regulation as a treatment target in psychosis and inform the development of larger controlled trials evaluating emotion-focused interventions in early psychosis care. The intervention could represent a scalable and practical psychosocial treatment to address emotional difficulties that are common but often under-treated in psychosis.

This study employing qualitative and quantitative methods to evaluate the group DBT skills training intervention and test its feasibility, and acceptability in individuals with psychosis. A single arm trial where DBT skills group delivered over 8-weeks, will be conducted. Thirty-two participants are planned to be enrolled in the trial. Participants will continue with their standard outpatient care during the trial. Outcome measures will be completed at study entry and post-treatment. For the qualitative component of the study, 15 post-intervention semi-structured interviews will be conducted.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 14-35 years old.
  • All gender identities are eligible to participate.
  • Being competent as demonstrated by comprehension of the study procedures, risks, benefits and their rights as a volunteer in the research study and willing to consent to study participation.
  • Meets criteria for a psychotic spectrum disorder as determined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, other specified schizophrenia spectrum disorder, or other unspecified schizophrenia spectrum disorder), or bipolar disorder with psychotic features, and is within 3 years of their initial diagnosis.

Exclusion criteria

  • Diagnosis of intellectual disability previously documented in the patient chart.
  • Acute suicidality requiring immediate life-saving intervention (i.e., inpatient psychiatric care).
  • Receiving any additional structured psychotherapy interventions during the study period.

Treatment and study plan

group DBT

Behavioral

DBT skills group delivered over 8-weeks

Primary outcomes

  1. Adherence

    Time frame: post treatment (8 weeks after baseline)

    Percent sessions attended

  2. Retention rates

    Time frame: post treatment (8 weeks after baseline)

    Percent participants who complete 8-week study.

  3. Attrition

    Time frame: post treatment (8 weeks after baseline)

    Percent participants that dropout at 8 weeks

  4. Client Satisfaction Questionnaire

    Time frame: post treatment (8 weeks after baseline)

    A Likert scale from 1-4, total scores range from 8-32, with higher scores indicating greater satisfaction.

  5. Timeline Follow Back (TLFB)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A self-report method for substance use, and will be used to quantify the amount/frequency of cannabis in the past 14 days.

Secondary outcomes

  1. Brief Psychiatric Rating Scale (BPRS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    a widely used instrument for the assessment of positive, negative and affective symptoms in individuals who have psychotic disorders. It consists of 18 symptom constructs.

  2. Scale for the Assessment of Negative Symptoms (SANS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    An instrument for measuring negative symptoms in schizophrenia. It assesses five symptom complexes to obtain clinical ratings of negative symptoms in participants with schizophrenia. They are: affective blunting; alogia (impoverished thinking); avolition/apathy; anhedonia/asociality; and disturbance of attention. Assessments are conducted on a six-point scale (0=not at all to 5=severe).

  3. Calgary Depression Scale for Schizophrenia (CDSS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    4-point Likert type scale (0, absent; 1, mild; 2, moderate; 3, severe) with nine items. It is a reliable scale, with high internal consistency (Cronbach's alpha = 0.855), and the CDSS is suitable for evaluating symptoms of depression in people at clinical high risk for psychosis

  4. State-Trait Anxiety Inventory (STAI)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.

  5. Borderline Symptom List (BSL-23)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A well-established self-rating instrument to assess the severity of borderline typical psychopathology. The BSL-23 assesses 23 feelings and experiences typically reported by BPD patients, refers to the last week and has a range from 0 = 'not at all' to 4 = 'very strong.

  6. Difficulties in emotion regulation scale (DERS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A 36-item self-report measure of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never [0-10%]") to 5 ("almost always [91-100%]")

  7. Global Functioning: Social and Role Scales

    Time frame: From enrollment to the end of treatment at 8 weeks

    Brief clinician-administered measures of social and role functioning, respectively, administered as a semi-structured interview with detailed anchors for ratings that address functional difficulties typically experienced by youth at risk for psychosis

  8. Connor-Davidson Resilience Scale (CD-RISC)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A 25-item self-report rating scale designed to assess resilience, with higher scores being an indicator of high resilience. Each item is rated on a 5-point scale ranging from not true at all or zero to true nearly all the time or four.

  9. Adolescent Alcohol and Drug Involvement Scale (AADIS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A clinician rated instrument which evaluates an adolescent's use of alcohol and other drugs

  10. Cannabis Use Disorders Identification Test-Revised (CUDIT-R)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A self-report tool developed that aim to distinguish between different levels of cannabis use, cannabis use disorders and stage of change (95). It contains 8 items, two each from the domains of consumption, cannabis problems (abuse), dependence, and psychological features

  11. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    A semi-structured clinical interview that assesses suicidal ideation severity, suicidal ideation intensity, and suicidal behavior

Study contacts

Contact information is provided by the study sponsor or research team.

Omair Husain

CONTACT

[email protected]

416-535-8501 ext. 36467

Sponsors and collaborators

Lead sponsor

Centre for Addiction and Mental Health

Other

Registry information

Official study title

Group Dialectical Behaviour Therapy (DBT) Skills Training for Individuals With First Episode Psychosis: a Feasibility Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 20, 2026
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.